Log In
Print
BCIQ
Print
Print this Print this
 

Imbruvica, ibrutinib (PCI-32765)

  Manage Alerts
Collapse Summary General Information
Company Pharmacyclics Inc.
DescriptionBruton's tyrosine kinase (Btk) inhibitor that covalently binds to cysteine residue 481
Molecular Target Bruton's tyrosine kinase (Btk)
Mechanism of ActionBruton's tyrosine kinase (Btk) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$21,975.0M

$150.0M

$825.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today